Strategic Advocates’s Editas Medicine EDIT Stock Holding History

Strategic Advocates’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,077	Closed	-$2.2K	–	360
2025 Q4	$2.2K	Hold	1,077	–	–	﹤0.01%	489
2025 Q3	$3.74K	Buy	+1,077	New	+$3.01K	﹤0.01%	437

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Strategic Advocates's EDIT Position: Q1 2026 in Review

Strategic Advocates sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 1,077 shares — an estimated $2.2K sold.

Strategic Advocates first reported a position in EDIT in Q3 2025 and held it in 2 quarters. The position peaked at $3.74K in Q3 2025. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Strategic Advocates reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 1,077 Editas Medicine shares in Q1 2026, an estimated $2.2K.
Strategic Advocates first reported a position in Editas Medicine in Q3 2025 and held it in 2 quarters.
Strategic Advocates's Editas Medicine position peaked at $3.74K in Q3 2025.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.